Skin Cancer News and Research RSS Feed - Skin Cancer News and Research

Skin cancer is the most common type of cancer in the U.S. It occurs in more than a million people each year, including many older people. There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma, and melanoma. Of the three, melanoma is the most serious. Skin cancer occurs when abnormal cells form and multiply in an uncontrolled way in the epidermis, or abnormal cells from the epidermis invade the dermis of the skin. Basal cell carcinoma, squamous cell carcinoma, and melanoma are skin cancers that are named for the epidermal cells from which they develop.
Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen Research & Development, LLC today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA (ibrutinib) to the U.S. Food and Drug Administration by its strategic partner Pharmacyclics, Inc. [More]
Researchers identify novel method to develop personalized vaccines for ovarian cancer

Researchers identify novel method to develop personalized vaccines for ovarian cancer

Researchers at the University of Connecticut have found a new way to identify protein mutations in cancer cells. The novel method is being used to develop personalized vaccines to treat patients with ovarian cancer. [More]
Scientists combine new type of nanoparticle with photodynamic therapy to kill cancer cells

Scientists combine new type of nanoparticle with photodynamic therapy to kill cancer cells

An international group of scientists led by Gang Han, PhD, at the University of Massachusetts Medical School, has combined a new type of nanoparticle with an FDA-approved photodynamic therapy to effectively kill deep-set cancer cells in vivo with minimal damage to surrounding tissue and fewer side effects than chemotherapy. This promising new treatment strategy could expand the current use of photodynamic therapies to access deep-set cancer tumors. [More]
SIRT6 protein inhibits liver and colon cancers, but promotes skin cancer caused by ultraviolet light

SIRT6 protein inhibits liver and colon cancers, but promotes skin cancer caused by ultraviolet light

A new study published in Cancer Research shows SIRT6—a protein known to inhibit the growth of liver and colon cancers—can promote the development of skin cancers by turning on an enzyme that increases inflammation, proliferation and survival of sun-damaged skin cells. [More]
Melanoma cells create own 'green light' signal to spread in the body

Melanoma cells create own 'green light' signal to spread in the body

CANCER RESEARCH UK scientists have discovered that melanoma cells are drawn to follow the 'trail' of a naturally-occurring molecule in the body, which directs this serious type of skin cancer to spread, according to research published today (Tuesday) in PLOS Biology. [More]
RNA molecules in tissue, urine samples can detect prostate cancer

RNA molecules in tissue, urine samples can detect prostate cancer

Researchers at Sanford-Burnham Medical Research Institute have identified a set of RNA molecules that are detectable in tissue samples and urine of prostate cancer patients but not in normal healthy individuals. [More]
Chronic contact allergy from metal orthopedic implant linked to aggressive form of skin cancer

Chronic contact allergy from metal orthopedic implant linked to aggressive form of skin cancer

In rare cases, patients with allergies to metals develop persistent skin rashes after metal devices are implanted near the skin. New research suggests these patients may be at increased risk of an unusual and aggressive form of skin cancer. [More]
NIH announces high-risk, high-reward grants for UCSF researchers

NIH announces high-risk, high-reward grants for UCSF researchers

UC San Francisco researchers received five awards announced this week by the National Institutes of Health (NIH) for high-risk, high-reward scientific research projects. Their work will focus on novel approaches for diagnosing and treating diseases ranging from autoimmune and chronic inflammatory diseases, to cancer, diabetes and neurological disorders. [More]
UCSF researchers receive five NIH awards for high-risk scientific research projects

UCSF researchers receive five NIH awards for high-risk scientific research projects

UC San Francisco researchers received five awards announced this week by the National Institutes of Health for high-risk, high-reward scientific research projects. Their work will focus on novel approaches for diagnosing and treating diseases ranging from autoimmune and chronic inflammatory diseases, to cancer, diabetes and neurological disorders. [More]
Gigapixel whole-body photographic camera may help doctors spot cancer early, save lives

Gigapixel whole-body photographic camera may help doctors spot cancer early, save lives

Melanoma is the fifth most common cancer type in the United States, and it's also the deadliest form of skin cancer, causing more than 75 percent of skin-cancer deaths. If caught early enough though, it is almost always curable. Now a camera, capable of taking snapshots of the entire human body and rendering high-resolution images of a patient's skin may help doctors spot cancer early and save lives. [More]
Cultural, historical forces contribute to rise in cases of melanoma

Cultural, historical forces contribute to rise in cases of melanoma

A century's worth of cultural and historical forces have contributed to the rise in the incidence of melanoma, including changes in fashion and clothing design, according to an intriguing, retrospective research study conducted by investigators in the Ronald O. Perelman Department of Dermatology at NYU Langone Medical Center. [More]
Combination treatment prevents disease progression in patients with advanced melanoma

Combination treatment prevents disease progression in patients with advanced melanoma

New data announced today has demonstrated that combinational treatment of cobimetinib with Zelboraf (vemurafenib), the first personalised medicine to extend life in the first-line setting for over 30 years, in patients with advanced melanoma (BRAFV600 mutation-positive) can prevent disease progression (progression-free survival; PFS) by 9.9 months compared to 6.2 months following treatment of vemurafenib alone. [More]
Circulating tumour cell clinical research collaboration announced between EKF Diagnostics and Massachusetts General Hospital

Circulating tumour cell clinical research collaboration announced between EKF Diagnostics and Massachusetts General Hospital

EKF Diagnostics, the global diagnostics company, announces that it has entered into a two year research collaboration with Massachusetts General Hospital (MGH), a global leader in successfully bridging innovative science with state-of-the-art clinical medicine, to develop PointMan™ assays that can effectively detect treatable cancer mutations in blood samples. [More]
Penn Medicine, Wistar Institute awarded NCI grants for four new melanoma research projects

Penn Medicine, Wistar Institute awarded NCI grants for four new melanoma research projects

Penn Medicine and The Wistar Institute have been awarded a prestigious $12.1 million SPORE grant from the National Cancer Institute. The five-year Specialized Programs of Research Excellence, or SPORE, grant will fund four new melanoma research projects that aim to translate fundamental laboratory discoveries into new therapeutics to treat melanoma and other skin cancers. [More]

Photoelectric therapy for non-melanoma skin cancer developed by Xstrahl

With a presence in over 500 clinics around the world, Xstrahl have drawn upon their vast clinical expertise to develop a revolutionary system that has been specifically designed for the treatment superficial skin cancers and skin conditions. [More]
Study uncovers new genetic risk factor for deadly skin cancer

Study uncovers new genetic risk factor for deadly skin cancer

Buffers that guard against damage to the ends of chromosomes could hold the key to a better understanding of malignant melanoma - the deadliest form of skin cancer - according to new research from the University of Leeds. [More]

Soldiers deployed to sunny climates face increased risk of skin cancer

Soldiers deployed to tropical and sunny climates are coming home with increased risk factors for a threat far from the battlefield: skin cancer. [More]
Novel genetic discovery identifies new avenues for prostate cancer treatment

Novel genetic discovery identifies new avenues for prostate cancer treatment

A genetic discovery out of the University of Pittsburgh School of Medicine is leading to a highly accurate test for aggressive prostate cancer and identifies new avenues for treatment. [More]
AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie today announced results from a Phase 3 pivotal study demonstrating that HUMIRA® (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules. [More]
Study evaluates impact of myPath Melanoma diagnostic test

Study evaluates impact of myPath Melanoma diagnostic test

Myriad Genetics, Inc. today presented results from a pivotal clinical utility study of the Myriad myPath- Melanoma test at the 2014 College of American Pathologists (CAP) annual meeting in Chicago, Ill. [More]